Epigenetics in metabolic dysfunction-associated steatohepatitis

被引:0
|
作者
Zhang, Yanru [1 ,2 ]
Ding, Ruike [1 ,2 ]
Hu, Liangshuo [3 ]
Liu, Enqi [1 ,2 ]
Qu, Pengxiang [1 ,2 ]
机构
[1] Xi An Jiao Tong Univ, Lab Anim Ctr, Hlth Sci Ctr, Xian 710061, Peoples R China
[2] Minist Educ China, Key Lab Environm & Genes Related Dis, Xian 710049, Peoples R China
[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
MASH; Epigenetics; Liver; DNA methylation; Histone modifications; Noncoding RNA; NONALCOHOLIC STEATOHEPATITIS; HEPATIC STEATOSIS; LIPID-METABOLISM; NONCODING RNAS; LIVER; EXPRESSION; DIET; HEPATOCYTES; FIBROSIS; INJURY;
D O I
10.1016/j.cellsig.2025.111684
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Metabolic dysfunction-associated steatohepatitis (MASH) is a complex disease involving genetics, environment, and lifestyle, with the potential to progress to liver fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). Although the pathogenesis of MASH is not fully clear, increasing evidence has indicated that epigenetics plays an important role in the genesis and progression of MASH, during which, as drastic changes in metabolites, epigenetics undergo drastic changes. Roles of chromatin structure, chromatin accessibility, DNA methylation, histone modification, and non-coding RNAs were considered as bridges of pathogenic factors and MASH. In this review, the research progress on the epigenetics of MASH was summarized, and indepth research and therapeutic strategies based on epigenetics is expected to bring new hope to MASH patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide
    Huang, Rui
    Zhang, Chunli
    Mo, Xiaodong
    Rao, Huiying
    CHINESE MEDICAL JOURNAL, 2025, 138 (02) : 127 - 129
  • [42] Untargeted lipidomic analysis of metabolic dysfunction-associated steatohepatitis in women with morbid obesity
    Bertran, Laia
    Capellades, Jordi
    Abello, Sonia
    Richart, Cristobal
    PLOS ONE, 2025, 20 (03):
  • [43] Thymidine Phosphorylase Imaging Probe for Differential Diagnosis of Metabolic dysfunction-associated Steatohepatitis
    Higashikawa, Kei
    Uehara, Riho
    Horiguchi, Sawako
    Shibata, Yuki
    Okubo, Naoto
    Mizuno, Yuki
    Yasui, Hironobu
    Ohnishi, Shunsuke
    Takeda, Hiroshi
    Kuge, Yuji
    MOLECULAR IMAGING AND BIOLOGY, 2024, 26 (06) : 1036 - 1045
  • [44] Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis
    Sabatini, Silvia
    Sen, Partho
    Carli, Fabrizia
    Pezzica, Samantha
    Rosso, Chiara
    Lembo, Erminia
    Verrastro, Ornella
    Daly, Ann
    Govaere, Olivier
    Cockell, Simon
    Hyotylainen, Tuulia
    Mingrone, Geltrude
    Bugianesi, Elisabetta
    Anstee, Quentin M.
    Oresic, Matej
    Gastaldelli, Amalia
    CELL REPORTS MEDICINE, 2024, 5 (11)
  • [45] Prognostic Relevance of Metabolic Dysfunction-associated Steatohepatitis for Patients with Chronic Hepatitis B
    Rugivarodom, Manus
    Pongpaibul, Ananya
    Chainuvati, Siwaporn
    Nimanong, Supot
    Chotiyaputta, Watcharasak
    Tanwandee, Tawesak
    Charatcharoenwitthaya, Phunchai
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2023, 11 (01) : 76 - 87
  • [46] Epigenetic regulation of thyroid hormone action in human metabolic dysfunction-associated steatohepatitis
    Naujack, Alison-Michelle
    Krause, Christin
    Britsemmer, Jan H.
    Taege, Natalie
    Mittag, Jens
    Kirchner, Henriette
    EUROPEAN THYROID JOURNAL, 2024, 13 (05)
  • [47] Humanized monoacylglycerol acyltransferase 2 mice develop metabolic dysfunction-associated steatohepatitis
    Corbalan, J. Jose
    Jagadeesan, Pranavi
    Frietze, Karla K.
    Taylor, Rulaiha
    Gao, Grace L.
    Gallagher, Grant
    Nickels Jr, Joseph T.
    JOURNAL OF LIPID RESEARCH, 2024, 65 (12)
  • [48] Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide
    Huang Rui
    Zhang Chunli
    Mo Xiaodong
    Rao Huiying
    中华医学杂志英文版, 2025, 138 (02)
  • [49] Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis
    Horn, Paul
    Norlin, Jenny
    Almholt, Kasper
    Viuff, Birgitte M.
    Galsgaard, Elisabeth D.
    Hald, Andreas
    Zosel, Franziska
    Demuth, Helle
    Poulsen, Svend
    Norby, Peder L.
    Rasch, Morten G.
    Vyberg, Mogens
    Fleckner, Jan
    Werge, Mikkel Parsberg
    Gluud, Lise Lotte
    Rink, Marco R.
    Shepherd, Emma
    Northall, Ellie
    Lalor, Patricia F.
    Weston, Chris J.
    Fog- Tonnesen, Morten
    Newsome, Philip N.
    ELIFE, 2024, 13
  • [50] Protective hepatocyte signals restrain liver fibrosis in metabolic dysfunction-associated steatohepatitis
    Steffani, Marcella
    Geng, Yana
    Pajvani, Utpal B.
    Schwabe, Robert F.
    JOURNAL OF CLINICAL INVESTIGATION, 2024, 134 (07):